强生(JNJ)的肺癌治疗组合在后期研究中取得成功

凤凰网港股2023-09-28

金吾财讯 | 强生(JNJ)公司周四表示，其癌症治疗组合达到了一项后期研究的主要目标，该研究测试了该组合对一种肺癌患者的治疗作用。该制药商表示，对研究数据的中期分析显示，与阿斯利康的癌症药物奥西替尼相比，“有利于”其抗体治疗Rybrevant和实验药物lazertinib的组合的趋势。强生表示，计划为即将召开的科学会议提交数据，包括有关该研究某些次要目标的更多细节。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2370771782?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-09-28 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2370771782","market":"hk","top_or_hot":-1,"title":"强生(JNJ)的肺癌治疗组合在后期研究中取得成功","media":"凤凰网港股","content":"<html><body><p>金吾财讯 | <a href=\"https://laohu8.com/S/JNJ\">强生</a>(JNJ)公司周四表示，其癌症治疗组合达到了一项后期研究的主要目标，该研究测试了该组合对一种肺癌患者的治疗作用。该制药商表示，对研究数据的中期分析显示，与<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>的癌症药物奥西替尼相比，“有利于”其抗体治疗Rybrevant和实验药物lazertinib的组合的趋势。强生表示，计划为即将召开的科学会议提交数据，包括有关该研究某些次要目标的更多细节。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生(JNJ)的肺癌治疗组合在后期研究中取得成功</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生(JNJ)的肺癌治疗组合在后期研究中取得成功\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-28 20:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hknews.szfuit.com/newRssInfo/feed?original_id=13a3667a45376493ec48f22eb35715ea><strong>凤凰网港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 强生(JNJ)公司周四表示，其癌症治疗组合达到了一项后期研究的主要目标，该研究测试了该组合对一种肺癌患者的治疗作用。该制药商表示，对研究数据的中期分析显示，与阿斯利康的癌症药物奥西替尼相比，“有利于”其抗体治疗Rybrevant和实验药物lazertinib的组合的趋势。强生表示，计划为即将召开的科学会议提交数据，包括有关该研究某些次要目标的更多细节。</p>\n\n<a href=\"http://hknews.szfuit.com/newRssInfo/feed?original_id=13a3667a45376493ec48f22eb35715ea\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1585245621.USD","symbol_name":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","start_time":0,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=13a3667a45376493ec48f22eb35715ea","article_id":"2370771782","we_media_id":"1002821290","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2370771782","pubTimestamp":1695904568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"凤凰网港股","introduction":"凤凰网港股","home_visible":1,"id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"summary":"金吾财讯 | 强生(JNJ)公司周四表示，其癌症治疗组合达到了一项后期研究的主要目标，该研究测试了该组合对一种肺癌患者的治疗作用。该制药商表示，对研究数据的中期分析显示，与阿斯利康的癌症药物奥西替尼相比，“有利于”其抗体治疗Rybrevant和实验药物lazertinib的组合的趋势。强生表示，计划为即将召开的科学会议提交数据，包括有关该研究某些次要目标的更多细节。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4007":"制药","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4550":"红杉资本持仓","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","SG9999002232.USD":"Allianz Global High Payout USD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4532":"文艺复兴科技持仓","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","JNJ":"强生","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4585":"ETF&股票定投概念","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4534":"瑞士信贷持仓","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4588":"碎股","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","BK4581":"高盛持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4592":"伊斯兰概念","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4504":"桥水持仓","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4568":"美国抗疫概念"},"translate_title":"Johnson & Johnson (JNJ) lung cancer treatment combination succeeds in later research","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"金吾财讯 | 强生(JNJ)公司周四表示，其癌症治疗组合达到了一项后期研究的主要目标，该研究测试了该组合对一种肺癌患者的治疗作用。该制药商表示，对研究数据的中期分析显示，与阿斯利康的癌症药物奥西替尼相比，“有利于”其抗体治疗Rybrevant和实验药物lazertinib的组合的趋势。强生表示，计划为即将召开的科学会议提交数据，包括有关该研究某些次要目标的更多细节。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2370771782","isCrawlerRequest":true}